Center for Diabetes Research
Copenhagen, Gentofte, 2900, Denmark
NCT Number: NCT03013296
Delinieation of GIP's effects during a meal in humans using GIP receptor antagonisation.
Looking for future studies?
Notify Me18 year–70 year
Male
Interventional
Not applicable
Copenhagen, Gentofte, 2900, Denmark
Aim: To evaluate the role of GIPR signalling in postprandial physiology, including lipid, bone and glucose homeostasis, using a naturally occurring GIP fragment, which antagonises the GIPR.
Twelve healthy men (age 18-70 years, BMI 19-27 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GIP-A
Placebo
Exendin[9-39]
Other names: Ex(9-39)
GIP-A + Exendin[9-39]
Time frame: 180 minutes
Serum C-peptide AUC. Primary outcome changed during the inclusion period (original = insulin levels) due to risk of misinterpretation/diverse hepatic insulin extraction).
University Hospital, Gentofte, Copenhagen
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04571008
Glucose Metabolism Disorders, Metabolic Diseases
St Louis, Missouri, United States
View Trial DetailsNCT06619834
Diabetes Mellitus, Endocrine System Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT05014204
Diabetes, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT05260021
Diabetes Mellitus, Diabetes Mellitus, Type 2
Los Angeles, California, United States
View Trial Details